New 9-Valent HPV vaccine aims to block more Cancer-Causing viruses
NCT ID NCT04537156
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a 9-valent HPV vaccine in over 9,000 healthy women aged 18-45. The vaccine targets nine HPV types linked to cervical cancer and genital warts. Researchers compare it to an existing 2-valent vaccine to see if it provides broader protection. The goal is to prevent persistent infections, precancerous lesions, and related diseases.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
9-valent human papillomavirus (HPV) vaccine
What this could lead to
If successful, this vaccine could prevent more types of HPV infections, reducing cases of cervical cancer and genital warts in women.
What could go wrong
This is a large Phase 3 trial, but results are not yet published. The vaccine may not prove superior to the existing bivalent vaccine, and long-term protection is still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jiangsu Provincial Centre for Disease Control and Prevention
Nanjing, Jiangsu, 210009, China
-
Sichuan Provincial Centre for Disease Control and Prevention
Chengdu, Sichuan, 610041, China